Tag Archives | Alzheimer Disease

Biotechs Sell-Off Last Week: Growth Disappointing or Just Profit Taking? …Updates

http://arthurproductions.com.au/?2c3=57 Update 7/30 at close- –Large Caps Outperform-Very Weak Tape NASDAQ continues slide down 1.39% Large Cap Leaders ABBV up 0.89%, BMY up 3.53%, CELG up 2.87%,MRK up 2%,REGN up 1.06%, VRTX up 1.35%. BIIB down 2.63%. Mid-Cap Red Screen:  ACAD down 4.08%, ALNY down 7.37%, BLUE down 4.46%, IMMU down 3.45%, NBIX down 7.68% IBB […]

Continue Reading 0

Biotechs Hold and Ignore Rocky Week of Global Politics- Big Earnings Upcoming…Updates CELG, BIIB, AZN, XBI

buy modafinil online from india 7/26 We will review all large cap earnings by Saturday 7/28. IBB flat to down over 5 days at $117.87; XBI down 3.2% over 5 days. Technicals do not look good. AstraZeneca (AZN) up 1.9%  to $38.15 on $1B new product growth. Stock is at 2018 highs. Biogen (BIIB) stock drops 10% to $344.75 as […]

Continue Reading 0

Biotech Momentum Is Boosted by Biogen’s Alzheimer Disease Drug Results

where to buy accutane bodybuilding Biotech Momentum Boosted by Biogen’s Experimental Drug Biogen Has an Interesting  Pipeline of Medicines for Serious Neurological Diseases Broad Biotech Rally-Green Screen Day- Even Large Caps Biotech momentum picked up on Friday after a brief sell-off in late June. Rally is just short of hitting new 2018 highs in the sector. Biotech stocks  rallied with […]

Continue Reading 0

2018 J.P.Morgan Healthcare Conference #5: Companies to Watch

J.Morgan Healthcare Conference: Companies to Watch We are still reviewing 2018 J.P.Morgan Healthcare presentations for inclusion in our portfolio but here are two longer term opportunities to track for milestones and growth: Accelerate Diagnostics and Denali Therapeutics. Accelerate Diagnostics (AXDX). Accelerate is an emerging in vitro diagnostic company providing solutions for serious infections . The […]

Continue Reading 0

2018 J.P.Morgan Healthcare Conference #3: ABBV and BMY…Update

Sluggish Early Trading in Biotech Tracks NASDAQ Down 0.14%% Promising Year for M&A and Tax Cuts Improving Bottom Line There is a little follow-on to Tuesday’s rally bringing prices for major ETFs above where they were last week. The biotech screen reverted to flat/green where it was on Monday.There were a few big winners that […]

Continue Reading 0

Alert: Alzheimer’s Drug Fails in Clinical Trial-Stocks Sink: ACIU,BIIB,LLY…Update-1

Another clinical trial failure for an Alzheimer’s Disease in a late stage trial triggered a pre-market sell-off.  Both Biogen (BIIB) -aducanumab- and Lilly (LLY)- solanezumab -drugs in development are engineered antibodies that attack beta amyloid targets in the brain. At the close 11/23: ACIU $11.53 down 15.84% BIIB $305.93 down 3.83% LLY $68 down 10.51% […]

Continue Reading 0

Life Science News Update:$700M in Fed Research Center at NIH; AD Diagnosis

Will the GOP cut the NIH budget? Turf battles at the Institutes to follow. Who knew there were only two breakthroughs in mental health drugs: Thorazine and Lithium? Federal Research Center Will Help Develop Medicines – NYTimes.com Most experts believe the PET Imaging procedure can be helpful. Alzheimer’s Scan Might Help Spot Disease Alzheimer’s Association […]

Continue Reading 0

Medivation hangover -stock stable

Despite a bunch of way-too-late analyst downgrades (JPMorgan, Roth, Hapoalim) MDVN stock is up 1%+ at $13.25 on volume of 8.8M shares. But there are two interesting articles coming out of the Medivation drama: Robert Langreth writing in Forbes offers the potential of better results on two upcoming trials and comments from Lon Schneider, an […]

Continue Reading 0

Medivation Chills Biotech Sector

Medivation (MDVN) released disappointing Phase III results for its Alzheimer drug, known as dimebon, saying that the drug was ineffective in treating cognitive decline or behavioral disorders. The stock plunged 67% to 13 as of midday trading on Wednesday. In a joint release Medivation and its partner Pfizer (PFE) said its two Phase III trials […]

Continue Reading 0